Recognized in both pre-and post-approval pharmacovigilance operationsDURHAM, N.C., May 01, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced it has been recognized as a “Leader” for pharmacovigilance (PV) operations by Everest Group in its annual Pharmacovigilance Operations PEAK Matrix® Assessment 2025. Fortrea’s top position was recognized in both pre-and post-approval PV operations in Everest Group’s proprietary framework, which assess ...